|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2009-10-5
|
|
pubmed:abstractText |
This study quantified the overall merit of adjunctive aripiprazole in major depressive disorder (MDD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1099-1557
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
2009 John Wiley & Sons, Ltd.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
965-72
|
|
pubmed:meshHeading |
pubmed-meshheading:19662630-Antidepressive Agents,
pubmed-meshheading:19662630-Antipsychotic Agents,
pubmed-meshheading:19662630-Depressive Disorder, Major,
pubmed-meshheading:19662630-Double-Blind Method,
pubmed-meshheading:19662630-Drug Therapy, Combination,
pubmed-meshheading:19662630-Female,
pubmed-meshheading:19662630-Humans,
pubmed-meshheading:19662630-Logistic Models,
pubmed-meshheading:19662630-Male,
pubmed-meshheading:19662630-Middle Aged,
pubmed-meshheading:19662630-Multicenter Studies as Topic,
pubmed-meshheading:19662630-Odds Ratio,
pubmed-meshheading:19662630-Piperazines,
pubmed-meshheading:19662630-Psychiatric Status Rating Scales,
pubmed-meshheading:19662630-Quinolones,
pubmed-meshheading:19662630-Randomized Controlled Trials as Topic,
pubmed-meshheading:19662630-Risk Assessment,
pubmed-meshheading:19662630-Risk Factors,
pubmed-meshheading:19662630-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
|
|
pubmed:affiliation |
University of Pittsburgh, PA 15261, USA. wisniew@edc.pitt.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
